ATARA Biotherapeutics (ATRA) Misses Q2 EPS by 2c

ATARA Biotherapeutics (NASDAQ: ATRA) reported Q2 EPS of ($0.68), $0.02 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $960 thousand versus the consensus estimate of $4.36 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.

You May Also Be Interested In

• KB Home (KBH) Tops Q3 EPS by 16c
• AutoZone (AZO) Tops Q4 EPS by $1.76, Misses on Revenue
• Goldman: 'Our key conclusion is that AI is likely to be credit-positive for banks', 'Rearming Our Overweight Stance on Banks'